<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="pmcid: 7384729387 doi: 10.1038/s41371-020-0387-4 : Review Article Covid-19 and the" exact="cardiovascular" post="system: a comprehensive review http://orcid.org/0000-0001-6864-8805AzevedoRafael Bellottihttp://orcid.org/0000-0002-4130-5148BotelhoBruna GoppHollandaJoÃ£o Victor GonÃ§alves"/>
 <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
 <result pre="Organization (WHO) declaration of COVID-19 as a global pandemic. Abstract" exact="Cardiac" post="injury in patients infected with the novel Coronavirus (COVID-19)"/>
 <result pre="evolution of COVID-19, emphasizing its impact and implications on the" exact="cardiovascular" post="system. The pathophysiology of severe acute respiratory syndrome coronavirus"/>
 <result pre="and implications on the cardiovascular system. The pathophysiology of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by overproduction"/>
 <result pre="implications on the cardiovascular system. The pathophysiology of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) is characterized by overproduction of"/>
 <result pre="on the cardiovascular system. The pathophysiology of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) is characterized by overproduction of inflammatory"/>
 <result pre="by overproduction of inflammatory cytokines (IL-6 and TNF-Î±) leading to" exact="systemic" post="inflammation and multiple organ dysfunction syndrome, acutely affecting the"/>
 <result pre="systemic inflammation and multiple organ dysfunction syndrome, acutely affecting the" exact="cardiovascular" post="system. HypertensionÂ (56.6%) and diabetes (33.8%) are the most"/>
 <result pre="dysfunction syndrome, acutely affecting the cardiovascular system. HypertensionÂ (56.6%) and" exact="diabetes" post="(33.8%) are the most prevalent comorbidities among individuals with"/>
 <result pre="important correlation between myocardial injury and inflammatory hyperactivity triggered by" exact="viral infection." post="Increased risk for myocardial infarction, fulminant myocarditis rapidly evolving"/>
 <result pre="between myocardial injury and inflammatory hyperactivity triggered by viral infection." exact="Increased" post="risk for myocardial infarction, fulminant myocarditis rapidly evolving with"/>
 <result pre="and inflammatory hyperactivity triggered by viral infection. Increased risk for" exact="myocardial infarction," post="fulminant myocarditis rapidly evolving with depressed systolic left ventricle"/>
 <result pre="triggered by viral infection. Increased risk for myocardial infarction, fulminant" exact="myocarditis" post="rapidly evolving with depressed systolic left ventricle function, arrhythmias,"/>
 <result pre="myocarditis rapidly evolving with depressed systolic left ventricle function, arrhythmias," exact="venous thromboembolism," post="and cardiomyopathies mimicking STEMI presentations are the most prevalent"/>
 <result pre="thromboembolism, and cardiomyopathies mimicking STEMI presentations are the most prevalent" exact="cardiovascular" post="complications described in patients with COVID-19. Moreover, SARS-CoV-2 tropism"/>
 <result pre="and implementation of optimal therapeutic strategies. Subject terms Cardiovascular diseases" exact="Diseases" post="Introduction Currently, the world is facing a pandemic caused"/>
 <result pre="Currently, the world is facing a pandemic caused by severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), etiological agent of COVID-19"/>
 <result pre="the world is facing a pandemic caused by severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), etiological agent of COVID-19 disease"/>
 <result pre="world is facing a pandemic caused by severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), etiological agent of COVID-19 disease [1]."/>
 <result pre="acute respiratory syndrome coronavirus 2 (SARS-CoV-2), etiological agent of COVID-19" exact="disease" post="[1]. The first signs of the new virus began"/>
 <result pre="China. In this century, two coronavirus epidemicsÂ occurred, the severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) in 2002 and the Middle"/>
 <result pre="In this century, two coronavirus epidemicsÂ occurred, the severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) in 2002 and the Middle East"/>
 <result pre="this century, two coronavirus epidemicsÂ occurred, the severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) in 2002 and the Middle East respiratory"/>
 <result pre="respiratory syndrome coronavirus (SARS-CoV) in 2002 and the Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) in 2012 [1]. SARS-CoV-2 presents a"/>
 <result pre="syndrome coronavirus (SARS-CoV) in 2002 and the Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) in 2012 [1]. SARS-CoV-2 presents a transmissibility"/>
 <result pre="viruses, with great capacity for fast mutations and recombination, causing" exact="respiratory" post="or intestinal infections in humans and animals [2]. The"/>
 <result pre="capacity for fast mutations and recombination, causing respiratory or intestinal" exact="infections" post="in humans and animals [2]. The SARS-CoV-2 infection occurs"/>
 <result pre="or intestinal infections in humans and animals [2]. The SARS-CoV-2" exact="infection" post="occurs through the coupling of S-protein located on the"/>
 <result pre="of COVID-19 are respiratory, varying from a mild presentation to" exact="acute" post="respiratory distress syndrome (ARDS), being potentially fatal.Â Moreover, as"/>
 <result pre="COVID-19 are respiratory, varying from a mild presentation to acute" exact="respiratory" post="distress syndrome (ARDS), being potentially fatal.Â Moreover, as in"/>
 <result pre="respiratory, varying from a mild presentation to acute respiratory distress" exact="syndrome" post="(ARDS), being potentially fatal.Â Moreover, as in other respiratory"/>
 <result pre="distress syndrome (ARDS), being potentially fatal.Â Moreover, as in other" exact="respiratory" post="infections, pre-existing CV diseases and risk factors can increase"/>
 <result pre="severity of COVID-19, leading to the aggravation and decompensation of" exact="chronic" post="underlying cardiac pathologies as well as acute-onset of new"/>
 <result pre="highlight four different aspects: (a) CV risk factors and established" exact="CV disease" post="is associated with a worse prognosis, (b) appearance of"/>
 <result pre="four different aspects: (a) CV risk factors and established CV" exact="disease" post="is associated with a worse prognosis, (b) appearance of"/>
 <result pre="disease is associated with a worse prognosis, (b) appearance of" exact="acute" post="CV complications in previously healthy individuals, (c) promising therapies"/>
 <result pre="retrospective studies, prospective studies, meta-analysis, and clinical guidelines regarding the" exact="cardiovascular" post="implications related to COVID-19. Articles with a central theme"/>
 <result pre="with a central theme diverging or not related to the" exact="cardiovascular" post="complications associated with SARS-CoV-2 infection were excluded from the"/>
 <result pre="or not related to the cardiovascular complications associated with SARS-CoV-2" exact="infection" post="were excluded from the revision. Articles that were not"/>
 <result pre="Articles that were not in English were also excluded. A" exact="total" post="of 35 citations were thoroughly reviewed to compose the"/>
 <result pre="evolution of COVID-19 are broad, ranging from asymptomatic to severe" exact="respiratory" post="failure requiring mechanical ventilation [3]. Therefore, to better understand"/>
 <result pre="of the disease. The first, or â€œmild,â€� phase, commonly of" exact="benign" post="evolution, occurs in the first 7 days with symptoms"/>
 <result pre="in the first 7 days with symptoms characteristic of upperÂ" exact="respiratory" post="tract infection. Nonspecific symptoms such as anosmia, ageusia, and"/>
 <result pre="7 days with symptoms characteristic of upperÂ respiratory tract infection." exact="Nonspecific" post="symptoms such as anosmia, ageusia, and gastrointestinal manifestations may"/>
 <result pre="saturation decrease [3], with signs and symptomsÂ suggesting progession for" exact="lower" post="respiratory tract infection.Â Laboratory evaluation reveals an increase of"/>
 <result pre="decrease [3], with signs and symptomsÂ suggesting progession for lower" exact="respiratory" post="tract infection.Â Laboratory evaluation reveals an increase of inflammatory"/>
 <result pre="activity and a prothrombotic component of the disease. Additionally, a" exact="chest" post="computed tomography (CT) may demonstrate a bilateral peripheral pulmonary"/>
 <result pre="disease. Additionally, a chest computed tomography (CT) may demonstrate a" exact="bilateral" post="peripheral pulmonary infiltrate in a well-defined ground-glass pattern,Â indicating"/>
 <result pre="Additionally, a chest computed tomography (CT) may demonstrate a bilateral" exact="peripheral" post="pulmonary infiltrate in a well-defined ground-glass pattern,Â indicating the"/>
 <result pre="a chest computed tomography (CT) may demonstrate a bilateral peripheral" exact="pulmonary" post="infiltrate in a well-defined ground-glass pattern,Â indicating the development"/>
 <result pre="infiltrate in a well-defined ground-glass pattern,Â indicating the development of" exact="viral pneumonia" post="[3]. About 5% evolve to the third phase, or"/>
 <result pre="in a well-defined ground-glass pattern,Â indicating the development of viral" exact="pneumonia" post="[3]. About 5% evolve to the third phase, or"/>
 <result pre="the third phase, or severe pneumonia, with worsening of the" exact="respiratory" post="condition, hypoxemia, and fever [3]. In a pathophysiological standpoint,"/>
 <result pre="expense of interleukin 6 and 2 (IL-6 and IL-2), and" exact="tumor" post="necrosis factor-Î± (TNF-Î±) [4]. Hypercytokinemia causes endothelial damage andÂ"/>
 <result pre="a state of hypercoagulability, thromboembolic events, and increased risk of" exact="bleeding" post="by disseminated intravascular coagulation (DIC). In addition, this phase"/>
 <result pre="of hypercoagulability, thromboembolic events, and increased risk of bleeding by" exact="disseminated intravascular coagulation" post="(DIC). In addition, this phase is characterized by cytopenias"/>
 <result pre="this phase is characterized by cytopenias and increased D-dimer [4]." exact="Respiratory" post="failure advances to ARDS. In chest CT, there is"/>
 <result pre="and increased D-dimer [4]. Respiratory failure advances to ARDS. In" exact="chest" post="CT, there is an exacerbation of the bilateralÂ pulmanary"/>
 <result pre="to multiple organ dysfunction syndrome. It is noteworthy that the" exact="systemic" post="inflammation promoted by SARS-CoV-2 plus hypercytokinaemia and hypercoagulability results"/>
 <result pre="myocardial injury with increase of troponin andÂ N-terminal prohormone of" exact="brain" post="natriuretic peptide (NT-proBNP), and consequentlyÂ CV complications, which will"/>
 <result pre="be further clarified below [4]. Cardiovascular complications Cardiovascular risk factors" exact="Hypertension" post="and diabetes are the most prevalent comorbiditiesÂ among individuals"/>
 <result pre="clarified below [4]. Cardiovascular complications Cardiovascular risk factors Hypertension and" exact="diabetes" post="are the most prevalent comorbiditiesÂ among individuals with COVID-19Â"/>
 <result pre="years; 39.7% female) were included, being the most frequent comorbidities" exact="hypertension" post="(56.6%), obesity (41.7%), and diabetes (33.8%) [5]. In general,Â"/>
 <result pre="female) were included, being the most frequent comorbidities hypertension (56.6%)," exact="obesity" post="(41.7%), and diabetes (33.8%) [5]. In general,Â recent studies"/>
 <result pre="being the most frequent comorbidities hypertension (56.6%), obesity (41.7%), and" exact="diabetes" post="(33.8%) [5]. In general,Â recent studies demonstrate that patients"/>
 <result pre="the worst evolution are the elderly, where the prevalence of" exact="hypertension" post="and diabetes is higher. Hypertension, as a chronic illness,"/>
 <result pre="evolution are the elderly, where the prevalence of hypertension and" exact="diabetes" post="is higher. Hypertension, as a chronic illness, implies a"/>
 <result pre="prevalence of hypertension and diabetes is higher. Hypertension, as a" exact="chronic" post="illness, implies a proinflammatory state, as seen in several"/>
 <result pre="chronic illness, implies a proinflammatory state, as seen in several" exact="infectious" post="disorders, as well as the attenuation of the innate"/>
 <result pre="particularly in critical patients. Furthermore, new evidence is surfacing linking" exact="hypertension" post="to a higher risk of developing severe disease due"/>
 <result pre="surfacing linking hypertension to a higher risk of developing severe" exact="disease" post="due to SARS-CoV-2 infection [7]. A retrospective cohort study"/>
 <result pre="a higher risk of developing severe disease due to SARS-CoV-2" exact="infection" post="[7]. A retrospective cohort study included 126 patients with"/>
 <result pre="COVID-19 without hypertension. Among hypertensives, 21.3% had more severe SARS-CoV-2" exact="infection" post="and higher death rate, 10.3% vs. 6.4%, when compared"/>
 <result pre="vs. 6.4%, when compared withÂ the non-hypertension group, indicating that" exact="hypertension" post="is a critical risk factor associated with poorer clinical"/>
 <result pre="CRP, procalcitonin, and IL-6 when compared to controls, indicating that" exact="hypertension" post="enhances inflammation in SARS-CoV-2 infection. Interestingly, hypertensive patients undergoing"/>
 <result pre="less profound inflammatory profile when compared with non-ARBs/ACEi treatment [8]." exact="Hypertension" post="seems to enhance the inflammatory profile in patients with"/>
 <result pre="inflammatory profile in patients with SARS-CoV-2 infection, inferring that resistant" exact="hypertension" post="possiblyÂ increases even more the risk for a more"/>
 <result pre="relationship, clinical evolution and eventualÂ risk of patients with resistant" exact="hypertension" post="and COVID-19 [9]. Myocarditis The SARS-CoV-2 infection, mainly in"/>
 <result pre="forms, apparently induce an aggression to the myocardium resulting in" exact="myocarditis" post="[1]. Shi et al. [10] reported that patients with"/>
 <result pre="or invasive ventilation (22.0% vs. 4.2%), and complications such as" exact="acute" post="kidney injury (8.5% vs. 0.3%) and coagulopathy (7.3% vs."/>
 <result pre="invasive ventilation (22.0% vs. 4.2%), and complications such as acute" exact="kidney injury" post="(8.5% vs. 0.3%) and coagulopathy (7.3% vs. 1.8%) [10]."/>
 <result pre="complications such as acute kidney injury (8.5% vs. 0.3%) and" exact="coagulopathy" post="(7.3% vs. 1.8%) [10]. Thus, troponin seems to be"/>
 <result pre="correlation between myocardial injury and inflammatory hyperactivity triggered by the" exact="viral infection" post="[10]. The pathophysiology regarding myocardial damage caused by COVID-19"/>
 <result pre="between myocardial injury and inflammatory hyperactivity triggered by the viral" exact="infection" post="[10]. The pathophysiology regarding myocardial damage caused by COVID-19"/>
 <result pre="infection [10]. The pathophysiology regarding myocardial damage caused by COVID-19" exact="infection" post="is not completely elucidated. However, studies highlight that the"/>
 <result pre="studies highlight that the pathogenesis may reflect a process of" exact="viral" post="replication and dissemination within the cardiomyocytes themselves. Moreover, it"/>
 <result pre="should be noted that hypercytokinaemia triggered by SARS-CoV-2 with consequent" exact="systemic" post="inflammation may induce myocardial damage [4, 11]. Based mainly"/>
 <result pre="[4, 11]. Based mainly on experimental studies in animals, the" exact="lower" post="expression of ACE2 in the myocardial tissue resulting in"/>
 <result pre="cardiac contractility strength, generating inotropic deficit, increased filling pressures, and" exact="acute" post="heart failure. Myocarditis related to SARS-CoV-2 has been described"/>
 <result pre="contractility strength, generating inotropic deficit, increased filling pressures, and acute" exact="heart" post="failure. Myocarditis related to SARS-CoV-2 has been described as"/>
 <result pre="Myocarditis related to SARS-CoV-2 has been described as an important" exact="acute" post="ventricular dysfunction associated with diffuse myocardial edema [13].Â Furthermore,"/>
 <result pre="related to SARS-CoV-2 has been described as an important acute" exact="ventricular dysfunction" post="associated with diffuse myocardial edema [13].Â Furthermore, it is"/>
 <result pre="been described as an important acute ventricular dysfunction associated with" exact="diffuse" post="myocardial edema [13].Â Furthermore, it is important to accentuateÂ"/>
 <result pre="to accentuateÂ the existence of reports revealing the occurrence of" exact="myocarditis" post="with fulminant evolution, complicated with pericarditis, pericardial effusion, and"/>
 <result pre="the occurrence of myocarditis with fulminant evolution, complicated with pericarditis," exact="pericardial effusion," post="and consequent cardiac tamponade [13]. Inciardi et al. [11]"/>
 <result pre="with fulminant evolution, complicated with pericarditis, pericardial effusion, and consequent" exact="cardiac tamponade" post="[13]. Inciardi et al. [11] emphasized that the myocardial"/>
 <result pre="emphasized that the myocardial involvement may occur even in the" exact="absence of" post="symptoms of upper respiratory tract infection. On physical examination,"/>
 <result pre="involvement may occur even in the absence of symptoms of" exact="upper respiratory tract infection." post="On physical examination, the presence of hypotension, tachycardia, tachypnea,"/>
 <result pre="may occur even in the absence of symptoms of upper" exact="respiratory" post="tract infection. On physical examination, the presence of hypotension,"/>
 <result pre="tachycardia, tachypnea, signs of low cardiac output, and a third" exact="heart" post="sound have been reported. It is noteworthy that the"/>
 <result pre="reported. It is noteworthy that the electrocardiogramÂ (ECG) may show" exact="diffuse" post="STÂ segment elevation with concave morphology in association with"/>
 <result pre="electrocardiogramÂ (ECG) may show diffuse STÂ segment elevation with concave" exact="morphology" post="in association with a significant increase in troponin,Â brain"/>
 <result pre="concave morphology in association with a significant increase in troponin,Â" exact="brain" post="natriuretic peptide (BNP)/NT-proBNP, and evidence of inflammatory activity [11].Â"/>
 <result pre="evidence of inflammatory activity [11].Â Also, transthoracic echocardiography can demonstrate" exact="diffuse" post="hypokinesia with myocardial thickening and decrease in the left"/>
 <result pre="left ventricular ejection fraction, while cardiac magnetic resonance imagingÂ reveals" exact="diffuse" post="interstitial edema [11]. It is important to keep in"/>
 <result pre="extracorporeal membrane oxygenation (ECMO) have been used inÂ patients with" exact="cardiogenic shock" post="and severe myocardial injury with hemodynamic impairment [1, 10,"/>
 <result pre="severityÂ and critical infection,Â due to the association with exacerbated" exact="systemic" post="inflammation [10â€&quot;12]. Heart failure Heart failure is an importantÂ"/>
 <result pre="infection,Â due to the association with exacerbated systemic inflammation [10â€&quot;12]." exact="Heart" post="failure Heart failure is an importantÂ cause of death"/>
 <result pre="to the association with exacerbated systemic inflammation [10â€&quot;12]. Heart failure" exact="Heart" post="failure is an importantÂ cause of death in patients"/>
 <result pre="differentÂ myocardialÂ aggression mechanisms such as direct myocardial injury by" exact="viral" post="action, indirect and direct inflammatory damage, O2 supplyâ€&quot;demand imbalance,"/>
 <result pre="events due to inflammatory destabilization of atheromatous plaquesÂ resulting in" exact="acute" post="myocardial dysfunction [11, 14]. Direct myocardial damage occursÂ as"/>
 <result pre="result of SARS-CoV-2Â interaction with myocardial tissue by binding the" exact="viral" post="glycoprotein Spike 1, after its activation by the serine"/>
 <result pre="increase of serum troponin in patients with or without previousÂ" exact="CV disease" post="has been directly related with an increase of plasmaticÂ"/>
 <result pre="of serum troponin in patients with or without previousÂ CV" exact="disease" post="has been directly related with an increase of plasmaticÂ"/>
 <result pre="prognosis. Nonetheless, the increase of troponin in individuals with previousÂ" exact="CV disease" post="characterized more severe clinical outcomes and higher mortality when"/>
 <result pre="Nonetheless, the increase of troponin in individuals with previousÂ CV" exact="disease" post="characterized more severe clinical outcomes and higher mortality when"/>
 <result pre="outcomes and higher mortality when compared to patientsÂ without previous" exact="heart" post="disease andÂ increased troponin values [11, 14].Â Hence, the"/>
 <result pre="and higher mortality when compared to patientsÂ without previous heart" exact="disease" post="andÂ increased troponin values [11, 14].Â Hence, the presence"/>
 <result pre="andÂ increased troponin values [11, 14].Â Hence, the presence of" exact="heart" post="disease is an important risk factor regarding the prognosis"/>
 <result pre="increased troponin values [11, 14].Â Hence, the presence of heart" exact="disease" post="is an important risk factor regarding the prognosis of"/>
 <result pre="risk factor regarding the prognosis of COVID-19 patients evolving withÂ" exact="acute" post="myocardialÂ injury [10, 14]. The hypothesis of the cumulative"/>
 <result pre="14]. The hypothesis of the cumulative effect of previousÂ CVÂ" exact="disease" post="and troponin increase was postulated due to the greater"/>
 <result pre="ACE2 receptors in postmortem cardiac pericytes extracted from patients with" exact="heart" post="disease compared with those without previous disease [15]. Acute"/>
 <result pre="receptors in postmortem cardiac pericytes extracted from patients with heart" exact="disease" post="compared with those without previous disease [15]. Acute myocardial"/>
 <result pre="from patients with heart disease compared with those without previous" exact="disease" post="[15]. Acute myocardial infarction Despite the level of scientific"/>
 <result pre="with heart disease compared with those without previous disease [15]." exact="Acute" post="myocardial infarction Despite the level of scientific evidence on"/>
 <result pre="heart disease compared with those without previous disease [15]. Acute" exact="myocardial infarction" post="Despite the level of scientific evidence on the subject"/>
 <result pre="the subject is still low, there are many studies correlating" exact="acute" post="myocardial injury (AMI) and the infection by SARS-CoV-2 [10,"/>
 <result pre="are many studies correlating acute myocardial injury (AMI) and the" exact="infection" post="by SARS-CoV-2 [10, 16]. According to the Fourth Universal"/>
 <result pre="the presence of AMI with clinical or laboratorial evidence of" exact="myocardial ischemia," post="being divided in five different pathophysiological types [16]. Some"/>
 <result pre="hypoxemia, immobilization, and, in some cases DIC, culminate in a" exact="prothrombotic state." post="Therefore, it can precipitate type-1 AMI, related to instability"/>
 <result pre="AMI, related to instability of the atherosclerotic plaque, leading to" exact="coronary thrombosis" post="and subsequent infarction [16, 17]. NeverthelessÂ , when compared"/>
 <result pre="related to instability of the atherosclerotic plaque, leading to coronary" exact="thrombosis" post="and subsequent infarction [16, 17]. NeverthelessÂ , when compared"/>
 <result pre="17]. NeverthelessÂ , when compared to patients hospitalized with severe" exact="pneumonia" post="due to other etiologies, individuals infected with SARS-CoV-2 have"/>
 <result pre="mechanisms [17]. Bioinformatics studies suggested that some binding proteins and" exact="viral" post="envelope glycoproteins may bind to both porphyrin and the"/>
 <result pre="decrease of available serum hemoglobin and, consequently, to hypoxemia, with" exact="pulmonary" post="and cardiac consequences. The inability to perform gas exchange"/>
 <result pre="explained by hypoxemia associated with increased cardiac demand due to" exact="systemic" post="infection. It is estimated that ~7% of patients have"/>
 <result pre="systemic infection. It is estimated that ~7% of patients have" exact="myocardial ischemia" post="or myocarditis [16]. In addition, it is important to"/>
 <result pre="infection. It is estimated that ~7% of patients have myocardial" exact="ischemia" post="or myocarditis [16]. In addition, it is important to"/>
 <result pre="is estimated that ~7% of patients have myocardial ischemia or" exact="myocarditis" post="[16]. In addition, it is important to note the"/>
 <result pre="mechanism. Patients previously submitted to angioplasty may, due to the" exact="hypercoagulability state" post="induced by the infection, present an increased incidence of"/>
 <result pre="AMI due to thrombotic occlusion of stent [16, 17]. Takotsubo" exact="cardiomyopathy" post="Takotsubo cardiomyopathy and its reverse presentation are important differential"/>
 <result pre="to thrombotic occlusion of stent [16, 17]. Takotsubo cardiomyopathy Takotsubo" exact="cardiomyopathy" post="and its reverse presentation are important differential diagnosis of"/>
 <result pre="ST segment elevation, in addition to transthoracic echocardiogram revealing left" exact="ventricular dysfunction," post="associated with hyperkinesia in apical ballooning, characteristic of Takotsubo"/>
 <result pre="dysfunction, associated with hyperkinesia in apical ballooning, characteristic of Takotsubo" exact="cardiomyopathy" post="[19]. It is important to note that the current"/>
 <result pre="potential trigger for Takotsubo cardiomyopathy, not only due to the" exact="respiratory" post="infection, but by the profound emotional stress caused by"/>
 <result pre="only due to the respiratory infection, but by the profound" exact="emotional" post="stress caused by the isolation period leading to an"/>
 <result pre="release of catecholamines [19]. Venous thromboembolism There is evidence that" exact="infection" post="by COVID-19 predisposes to a prothrombotic state by direct"/>
 <result pre="There is evidence that infection by COVID-19 predisposes to a" exact="prothrombotic state" post="by direct mechanisms (microvasculitis due to viral damage), indirect"/>
 <result pre="to a prothrombotic state by direct mechanisms (microvasculitis due to" exact="viral" post="damage), indirect mechanisms (downregulation of ACE2 receptor, hypoxia, and"/>
 <result pre="to social isolation) [17, 20]. According to recent studies, this" exact="prothrombotic state" post="could increase the risk of arterial thrombosis but also"/>
 <result pre="studies, this prothrombotic state could increase the risk of arterial" exact="thrombosis" post="but also of venous thromboembolism, such as deep vein"/>
 <result pre="could increase the risk of arterial thrombosis but also of" exact="venous thromboembolism," post="such as deep vein thrombosisÂ (DVT) and pulmonary thromboembolism"/>
 <result pre="of venous thromboembolism, such as deep vein thrombosisÂ (DVT) and" exact="pulmonary" post="thromboembolism (PTE) described in patients with severe infection by"/>
 <result pre="(DVT) and pulmonary thromboembolism (PTE) described in patients with severe" exact="infection" post="by SARS-CoV-2 [20]. This pathophysiological mechanism is supported by"/>
 <result pre="high sensitivity and specificity for the presence of thrombi in" exact="chest" post="angiotomography [20]. A Chinese study with 449 patients, of"/>
 <result pre="who used or did not use heparin, but it was" exact="lower" post="among those who used heparin in the subgroup with"/>
 <result pre="in the subgroup with D-dimer six times greater than the" exact="upper" post="limit (40.0% vs. 64.2%, pâ€‰=â€‰0.029) and with sepsis-induced coagulopathy"/>
 <result pre="the upper limit (40.0% vs. 64.2%, pâ€‰=â€‰0.029) and with sepsis-induced" exact="coagulopathy" post="scoreâ€‰â‰¥â€‰4 (32.8% vs. 52.4%, pâ€‰=â€‰0.017) [21]. Thus, the anticoagulant"/>
 <result pre="COVID-19 based on serum D-dimer levels has been preconized [21]." exact="Arrhythmias" post="There are few reports in the literature regarding cardiac"/>
 <result pre="no clear pathophysiological correlation. The potential mechanism seems to be" exact="viral" post="myocarditis caused by SARS-CoV-2 [19]. Fulminant myocarditis associated with"/>
 <result pre="clear pathophysiological correlation. The potential mechanism seems to be viral" exact="myocarditis" post="caused by SARS-CoV-2 [19]. Fulminant myocarditis associated with cardiogenic"/>
 <result pre="seems to be viral myocarditis caused by SARS-CoV-2 [19]. Fulminant" exact="myocarditis" post="associated with cardiogenic shock may be associated with the"/>
 <result pre="viral myocarditis caused by SARS-CoV-2 [19]. Fulminant myocarditis associated with" exact="cardiogenic shock" post="may be associated with the development of both ventricular"/>
 <result pre="may develop re-entry points in the electrical circuit, evolving with" exact="ventricular tachycardia" post="and ventricular fibrillation [22, 23]. Supporting this hypothesis, some"/>
 <result pre="points in the electrical circuit, evolving with ventricular tachycardia and" exact="ventricular fibrillation" post="[22, 23]. Supporting this hypothesis, some reports describe a"/>
 <result pre="in the electrical circuit, evolving with ventricular tachycardia and ventricular" exact="fibrillation" post="[22, 23]. Supporting this hypothesis, some reports describe a"/>
 <result pre="correlated the increase in NT-ProBNP levels with the onset of" exact="malignant" post="arrhythmias, suggesting the relationship between acute myocarditis and arrhythmias."/>
 <result pre="with the onset of malignant arrhythmias, suggesting the relationship between" exact="acute" post="myocarditis and arrhythmias. However, it is necessary to keep"/>
 <result pre="the onset of malignant arrhythmias, suggesting the relationship between acute" exact="myocarditis" post="and arrhythmias. However, it is necessary to keep in"/>
 <result pre="disorder, causing arrhythmias potentially related to potassium disorders [22]. Moreover," exact="transient" post="complete atrioventricular block was also described in critical patient,"/>
 <result pre="causing arrhythmias potentially related to potassium disorders [22]. Moreover, transient" exact="complete" post="atrioventricular block was also described in critical patient, raising"/>
 <result pre="arrhythmias potentially related to potassium disorders [22]. Moreover, transient complete" exact="atrioventricular block" post="was also described in critical patient, raising the possibility"/>
 <result pre="was also described in critical patient, raising the possibility of" exact="myocarditis" post="or due to increase of pulmonary artery pressure [22,"/>
 <result pre="raising the possibility of myocarditis or due to increase of" exact="pulmonary" post="artery pressure [22, 23]. Antimalarial and antiviral use during"/>
 <result pre="Antimalarial and antiviral use during COVID-19 pandemic: impact on the" exact="cardiovascular" post="system TheÂ ECG plays a key role in monitoring"/>
 <result pre="the QT interval and consequently with an arrhythmogenic potential for" exact="malignant" post="ventricular arrhythmias, especially polymorphic ventricular tachycardia with enlarged QTÂ"/>
 <result pre="with an arrhythmogenic potential for malignant ventricular arrhythmias, especially polymorphic" exact="ventricular tachycardia" post="with enlarged QTÂ interval (Torsades des Pointes) [23]. It"/>
 <result pre="with more severe COVID-19 due to their potential benefit in" exact="viral" post="RNA synthesis inhibition, diminishing RNA translation and viral exocytosis"/>
 <result pre="benefit in viral RNA synthesis inhibition, diminishing RNA translation and" exact="viral" post="exocytosis in host cells. In a cohort of 61"/>
 <result pre="that critical SARS-CoV-2 can be associated with hypercoagulability and a" exact="prothrombotic state" post="[28, 29]. RAAS and SARS-CoV-2 The interaction between theÂ"/>
 <result pre="the most commonly prescribed for the treatment of hypertension, diabetes," exact="and heart" post="failure worldwide, clinical conditions that are strongly associated with"/>
 <result pre="most commonly prescribed for the treatment of hypertension, diabetes, and" exact="heart" post="failure worldwide, clinical conditions that are strongly associated with"/>
 <result pre="of COVID-19 [30]. Some studies suggest that the cardiac damage" exact="secondary" post="to SARS-CoV-2 may be linked to ACE2, present in"/>
 <result pre="deactivation may play a harmful role in the development of" exact="respiratory" post="failure and its progression [30]. It is important to"/>
 <result pre="it inhibits angiotensin II activity [30, 35]. Likewise, individuals with" exact="hypertension" post="would have a higher expression of ACE2 secondary to"/>
 <result pre="individuals with hypertension would have a higher expression of ACE2" exact="secondary" post="to the use of RAAS inhibitors, which would potentially"/>
 <result pre="the use of RAAS inhibitors, which would potentially increase the" exact="susceptibility to" post="infection by SARS-CoV-2. In animal models, the use of"/>
 <result pre="of RAAS inhibitors, which would potentially increase the susceptibility to" exact="infection" post="by SARS-CoV-2. In animal models, the use of these"/>
 <result pre="retrospective study with 12,594 individuals evaluating the relation between previous" exact="hypertension" post="treatment with ACEi, ARBs, Î²-blockers, calcium-channel blockers, or thiazide"/>
 <result pre="between the use of these drugs and more severe SARS-CoV-2" exact="infection" post="was demonstrated [33]. Therefore, ACEi/ARBs are possibly potential drugs"/>
 <result pre="combination with IL-6R inhibitors towards inflammation attenuation in patients with" exact="hypertension" post="and COVID-19, requiring more robust evidence through randomized controlled"/>
 <result pre="with formal indication during the pandemic. Current evidence indicates that" exact="hypertension" post="per se might be a risk factor associated with"/>
 <result pre="and worse outcomes in patients with COVID-19, particularly patients with" exact="uncontrolled" post="hypertension, and that controlled hypertension specifically with RAAS blocker"/>
 <result pre="with COVID-19, particularly patients with uncontrolled hypertension, and that controlled" exact="hypertension" post="specifically with RAAS blocker therapy might be associated with"/>
 <result pre="blocker therapy might be associated with more favorable outcomes. Conclusion" exact="Hypertension" post="is strongly associated with SARS-CoV-2 infection possibly due to"/>
 <result pre="more favorable outcomes. Conclusion Hypertension is strongly associated with SARS-CoV-2" exact="infection" post="possibly due to the proinflammatory state of this chronic"/>
 <result pre="SARS-CoV-2 infection possibly due to the proinflammatory state of this" exact="chronic" post="illness in addition to the hypercytokinaemia that occurs in"/>
 <result pre="a prevalent complication in hospitalized patients, with or without previousÂ" exact="CV disease," post="and presents a significant association with in-hospital mortality and"/>
 <result pre="prognosis marker. In addition, myocardial insult was associated with severe" exact="ventricular dysfunction" post="and higher incidence of ventricular arrhythmia, mainly evidenced through"/>
 <result pre="they have no conflict of interest. References References 1.ClerkinKJFriedJARaikhelkarJSayerGGriffinJMMasoumiAet al.Coronavirus" exact="disease" post="2019 (COVID-19) and cardiovascular diseaseCirculation202014116485510.1161/CIRCULATIONAHA.120.04694132200663 2.HoffmannMKleine-WeberHSchroederSKrÃ¼gerNHerrlerTErichsenSet al.SARS-CoV-2 cell entry"/>
 <result pre="of interest. References References 1.ClerkinKJFriedJARaikhelkarJSayerGGriffinJMMasoumiAet al.Coronavirus disease 2019 (COVID-19) and" exact="cardiovascular" post="diseaseCirculation202014116485510.1161/CIRCULATIONAHA.120.04694132200663 2.HoffmannMKleine-WeberHSchroederSKrÃ¼gerNHerrlerTErichsenSet al.SARS-CoV-2 cell entry depends on ACE2 and"/>
 <result pre="protease inhibitorCell20201812718010.1016/j.cell.2020.02.05232142651 3.WuZMcGooganJMCharacteristics of and important lessons from the coronavirus" exact="disease" post="2019 (COVID-19) outbreak in ChinaJAMA202032312394210.1001/jama.2020.2648 4.YeQWangBMaoJThe pathogenesis and treatment"/>
 <result pre="hospitalized with COVID-19 in the New York City areaJAMA20203232052910.1001/jama.2020.6775 6.ZuinMRigatelliGZulianiGRigatelliAMazzaARonconLArterial" exact="hypertension" post="and risk of death in patients with COVID-19 infection:"/>
 <result pre="single-center retrospective studyHypertension20207651810.1161/HYPERTENSIONAHA.120.1514332348166 9.BarbaroNRFontanaVModoloRDe FariaAPSabbatiniARFonsecaFet al.Increased arterial stiffness in resistant" exact="hypertension" post="is associated with inflammatory biomarkersBlood Press20152471310.3109/08037051.2014.94071025061978 10.Shi S, Qin"/>
 <result pre="Cai Y, Liu T, Yang F et al. Association of" exact="Cardiac" post="Injury With Mortality in Hospitalized Patients With COVID-19 in"/>
 <result pre="Zaccone G, Italia L, Raffo M, Tomasoni D, et al." exact="Cardiac" post="Involvement in a Patient With Coronavirus Disease 2019 (COVID-19)."/>
 <result pre="D, et al. Cardiac Involvement in a Patient With Coronavirus" exact="Disease" post="2019 (COVID-19). JAMA Cardiol. 2020;5:1â€&quot;6. 10.1001/jamacardio.2020.1096. 12.GuoJHuangZLvJCoronavirus disease 2019"/>
 <result pre="With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;5:1â€&quot;6. 10.1001/jamacardio.2020.1096. 12.GuoJHuangZLvJCoronavirus" exact="disease" post="2019 (COVID-19) and cardiovascular disease: a viewpoint on the"/>
 <result pre="(COVID-19). JAMA Cardiol. 2020;5:1â€&quot;6. 10.1001/jamacardio.2020.1096. 12.GuoJHuangZLvJCoronavirus disease 2019 (COVID-19) and" exact="cardiovascular" post="disease: a viewpoint on the potential influence of angiotensin-converting"/>
 <result pre="enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe" exact="acute" post="respiratory syndrome coronavirus 2 infectionJ Am Heart Assoc20209e01621910.1161/JAHA.120.01621932233755 13.HuaAOâ€™GallagherKSadoDByrneJLife-threatening"/>
 <result pre="inhibitors/angiotensin receptor blockers on onset and severity of severe acute" exact="respiratory" post="syndrome coronavirus 2 infectionJ Am Heart Assoc20209e01621910.1161/JAHA.120.01621932233755 13.HuaAOâ€™GallagherKSadoDByrneJLife-threatening cardiac"/>
 <result pre="receptor blockers on onset and severity of severe acute respiratory" exact="syndrome" post="coronavirus 2 infectionJ Am Heart Assoc20209e01621910.1161/JAHA.120.01621932233755 13.HuaAOâ€™GallagherKSadoDByrneJLife-threatening cardiac tamponade"/>
 <result pre="severity of severe acute respiratory syndrome coronavirus 2 infectionJ Am" exact="Heart" post="Assoc20209e01621910.1161/JAHA.120.01621932233755 13.HuaAOâ€™GallagherKSadoDByrneJLife-threatening cardiac tamponade complicating myo-pericarditis in COVID-19Eur Heart"/>
 <result pre="acute respiratory syndrome coronavirus 2 infectionJ Am Heart Assoc20209e01621910.1161/JAHA.120.01621932233755 13.HuaAOâ€™GallagherKSadoDByrneJLife-threatening" exact="cardiac tamponade" post="complicating myo-pericarditis in COVID-19Eur Heart J202041213010.1093/eurheartj/ehaa25332227076 14.Guo T, Fan"/>
 <result pre="Am Heart Assoc20209e01621910.1161/JAHA.120.01621932233755 13.HuaAOâ€™GallagherKSadoDByrneJLife-threatening cardiac tamponade complicating myo-pericarditis in COVID-19Eur" exact="Heart" post="J202041213010.1093/eurheartj/ehaa25332227076 14.Guo T, Fan Y, Chen M, Wu X,"/>
 <result pre="al. Cardiovascular Implications of Fatal Outcomes of Patients with Coronavirus" exact="Disease" post="2019 (COVID-19). JAMA Cardiol. 2020;5:1â€&quot;8. 10.1001/jamacardio.2020.1017. 15.ChenLLiXChenMFengYXiongCThe ACE2 expression"/>
 <result pre="(COVID-19). JAMA Cardiol. 2020;5:1â€&quot;8. 10.1001/jamacardio.2020.1017. 15.ChenLLiXChenMFengYXiongCThe ACE2 expression in human" exact="heart" post="indicates new potential mechanism of heart injury among patients"/>
 <result pre="ACE2 expression in human heart indicates new potential mechanism of" exact="heart" post="injury among patients infected with SARS-CoV-2Cardiovasc Res2020116109710010.1093/cvr/cvaa07832227090 16.ThygesenKAlpertJSJaffeASChairmanBRBaxJJMorrowDAet al.Executive"/>
 <result pre="with SARS-CoV-2Cardiovasc Res2020116109710010.1093/cvr/cvaa07832227090 16.ThygesenKAlpertJSJaffeASChairmanBRBaxJJMorrowDAet al.Executive group on behalf of the" exact="Joint" post="European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American"/>
 <result pre="Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American" exact="Heart" post="Association (AHA)/World Heart Federation (WHF) Task Force for the"/>
 <result pre="of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World" exact="Heart" post="Federation (WHF) Task Force for the Universal Definition of"/>
 <result pre="the possible pathophysiology and proposed guideline for diagnosis and management." exact="Heart" post="Rhythm. 2020;S1547-5271:30422â€&quot;7. 20.BikdeliBMadhavanMVJimenezDChuichTDreyfusIDrigginEet al.COVID-19 and thrombotic or thromboembolic disease:"/>
 <result pre="21.TangNBaiHChenXGongJLiDSunZAnticoagulant treatment is associated with decreased mortality in severe coronavirus" exact="disease" post="2019 patients with coagulopathyJ Thromb Haemost2020181094910.1111/jth.1481732220112 22.Lakkireddy DR, Chung"/>
 <result pre="for cardiac electrophysiology during the coronavirus (COVID-19) pandemic from the" exact="Heart" post="Rhythm Society COVID-19 Task Force; Electrophysiology Section of the"/>
 <result pre="Heart Rhythm Society COVID-19 Task Force; Electrophysiology Section of the" exact="American" post="College of Cardiology; and the Electrocardiography and Arrhythmias Committee"/>
 <result pre="of the American College of Cardiology; and the Electrocardiography and" exact="Arrhythmias" post="Committee of the Council on Clinical Cardiology, American Heart"/>
 <result pre="Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology," exact="American" post="Heart Association. Heart Rhythm 2020; S1547-5271:30289â€&quot;7. 23.Wu C-I, Postema"/>
 <result pre="and Arrhythmias Committee of the Council on Clinical Cardiology, American" exact="Heart" post="Association. Heart Rhythm 2020; S1547-5271:30289â€&quot;7. 23.Wu C-I, Postema PG,"/>
 <result pre="Committee of the Council on Clinical Cardiology, American Heart Association." exact="Heart" post="Rhythm 2020; S1547-5271:30289â€&quot;7. 23.Wu C-I, Postema PG, Arbelo E,"/>
 <result pre="Bezzina CR, Napolitano C, et al. SARS-CoV-2, COVID-19 and inherited" exact="arrhythmia" post="syndromes. Heart Rhythm 2020;S1547-5271:30285-X. 24.TangWCaoZHanMWangZChenJSunWet al.Hydroxychloroquine in patients with"/>
 <result pre="Napolitano C, et al. SARS-CoV-2, COVID-19 and inherited arrhythmia syndromes." exact="Heart" post="Rhythm 2020;S1547-5271:30285-X. 24.TangWCaoZHanMWangZChenJSunWet al.Hydroxychloroquine in patients with mainly mild"/>
 <result pre="24.TangWCaoZHanMWangZChenJSunWet al.Hydroxychloroquine in patients with mainly mild to moderate coronavirus" exact="disease" post="2019: open label, randomised controlled trialBMJ2020369m184910.1136/bmj.m184932409561 25.Mercuro NJ, Yen"/>
 <result pre="without concomitant azithromycin among hospitalized patients testing positive for coronavirus" exact="disease" post="2019 (COVID-19). JAMA Cardiol. 2020;e201834. 10.1001/jamacardio.2020.1834 26.HancoxJCHasnainMViewegWVCrouseELBaranchukAAzithromycin, cardiovascular risks,"/>
 <result pre="for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;e201834. 10.1001/jamacardio.2020.1834 26.HancoxJCHasnainMViewegWVCrouseELBaranchukAAzithromycin," exact="cardiovascular" post="risks, QTc interval prolongation, torsade de pointes, and regulatory"/>
 <result pre="et al. Hypertension, the renin-angiotensin system, and the risk of" exact="lower" post="respiratory tract infections and lung injury: implications for COVID-19."/>
 <result pre="al. Hypertension, the renin-angiotensin system, and the risk of lower" exact="respiratory" post="tract infections and lung injury: implications for COVID-19. Cardiovasc"/>
 <result pre="the renin-angiotensin system, and the risk of lower respiratory tract" exact="infections" post="and lung injury: implications for COVID-19. Cardiovasc Res. 2020."/>
</results>
